J, V., GR, B., R, B., C, D., C, P., J, D., . . . Putensen, C. (2005). Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment. Critical Care Medicine, 33(10), 2266. https://doi.org/10.1097/01.ccm.0000181729.46010.83
Chicago Style (17th ed.) CitationJ, Vincent, et al. "Drotrecogin Alfa (activated) Treatment in Severe Sepsis from the Global Open-label Trial ENHANCE: Further Evidence for Survival and Safety and Implications for Early Treatment." Critical Care Medicine 33, no. 10 (2005): 2266. https://doi.org/10.1097/01.ccm.0000181729.46010.83.
MLA (9th ed.) CitationJ, Vincent, et al. "Drotrecogin Alfa (activated) Treatment in Severe Sepsis from the Global Open-label Trial ENHANCE: Further Evidence for Survival and Safety and Implications for Early Treatment." Critical Care Medicine, vol. 33, no. 10, 2005, p. 2266, https://doi.org/10.1097/01.ccm.0000181729.46010.83.
